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Background: Recent genome-wide association studies (GWAS) have shown that single nucleotide polymorphisms
(SNPs) in the Chr9p21 region are associated with coronary artery disease (CAD). Most of the SNPs identified in this
region are non-coding SNPs, suggesting that they may influence gene expression by cis or trans mechanisms to
affect disease susceptibility. Since all cells from an individual have the same DNA sequence variations, levels of gene
expression in immortalized cell lines can reflect the functional effects of DNA sequence variations that influence or
regulate gene expression. The objective of this study is to evaluate the functional consequences of the risk variants
in the Chr9p21 region on gene expression.
Methods: We examined the association between the variants in the Chr9p21 region and the transcript-level mRNA
expression of the adjacent genes (cis) as well as all other genes across the whole genome (trans) from transformed
beta-lymphocytes in 801 non-Hispanic white participants from The Genetic Epidemiology Network of Arteriopathy
(GENOA) study.
Results: We found that the CAD risk variants in the Chr9p21 region were significantly associated with the mRNA
expression of the ANRIL transcript ENST00000428597 (p = 8.58e-06). Importantly, a few distant transcripts were also found
to be associated with the variants in this region, including the well-known CAD risk gene ABCA1 (p = 1.01e-05).
Gene enrichment testing suggests that retinol metabolism, N-Glycan biosynthesis, and TGF signaling pathways
may be involved.
Conclusion: These results suggest that the effect of risk variants in the Chr9p21 region on susceptibility to CAD is
likely to be mediated through both cis and trans mechanisms.
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Atherosclerosis is a condition in which plaque builds up
within the walls of the coronary arteries that can lead to a
decreased supply of oxygen-rich blood to the heart muscle.
Over time, the accumulation of plaques within the coron-
ary arteries can weaken the heart muscle and lead to heart
failure and arrhythmias. The end result is coronary artery
disease (CAD), which is the leading cause of death in the
United States and many western countries [1-3]. Genetic
epidemiological studies of families and twins have sug-
gested that genetic mechanisms contribute to CAD suscep-
tibility after adjusting for other major non-genetic risk* Correspondence: zhaowei@umich.edu
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unless otherwise stated.factors [4]. In particular, genome-wide association studies
(GWAS) of common SNPs have found that single nucleo-
tide polymorphisms (SNPs) in the Chr9p21 region are as-
sociated with CAD in populations with European ancestry
[5-10]. This association was later replicated in many other
ethnicities, including Asians and Hispanics [11-13]. In
addition to CAD, this locus has also been found to be asso-
ciated with many other cardiovascular traits, including
stroke [14], aneurysm [15,16] and peripheral artery disease
[17]. This suggests the Chr9p21 region has broad effects
on the cardiovascular system.
The Chr9p21 haplotype block is a 113.5-kb region from
base pair 22,012,420 to 22,125,915 on chromosome 9 that
contains multiple SNPs that are in high linkage disequilib-
rium [18]. Even though the association between CAD andhis is an Open Access article distributed under the terms of the Creative
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many different studies and different ethnicities [5-13], the
fact that the SNP associated with CAD in GWAS does
not fall within gene boundaries makes the interpretation
of the association difficult. Moreover, the association be-
tween the Chr9p21 region and CAD is independent of any
traditional risk factors, such as hypertension or lipid pro-
file [5-7]. All of this evidence suggests that the Chr9p21
region affects atherosclerosis through a novel mechanism
that is yet to be discovered.
Genetic variants can affect RNA expression through ei-
ther cis or trans mechanisms or both. In this paper, the cis
effect refers to the effects of the genetic variants of the
Chr9p21 region on the genes within the same region. The
effects of the variants on all other genes are referred to as
a trans effect. The cis effect of the Chr9p21 region has
been investigated by several studies. There are four genes
that are adjacent to the region of chromosome 9p21,
which are CDKN2A, CDKN2B, ANRIL and C9orf53.
CDKN2A and CDKN2B are cyclin-dependent kinase in-
hibitors and are known tumor suppressors [19]. ANRIL,
also known as CKDN2B-AS, is a non-coding RNA [20]
and C9orf53 is an open reading frame. The functions of
ANRIL and C9orf53 are not clear. Several studies have ex-
amined the genetic effect of the identified risk variants in
this region on the abundance of mRNA level of these
genes in a variety of cells and tissues [21-27]. The majority
of these studies found robust associations between ANRIL
expression and the Chr9p21 genotypes. All of them sug-
gest an important role for ANRIL in the susceptibility of
CAD. However, all of these studies have examined only a
small number of CAD risk SNPs. There is no evidence so
far that the identified risk SNPs are the true functional
SNPs. Thus, a larger range of survey, including all of the
common and rare variants in the region, is needed. More-
over, alternative splicing plays an important role in the
gene expression. Investigating transcript level mRNA
abundance, as opposed to the whole gene level, would
lend insight into understanding the function. Lastly, des-
pite the importance of the Chr9p21 region, there is no
study that particularly investigated the trans effects of the
region, which may play a more proximal role on athero-
sclerosis than the cis effects [28,29].
The Genetic Epidemiology Network of Arteriopathy
Study (GENOA), a network in the Family Blood Pressure
Program [30], is a community-based study that recruited
sibships with at least two adults with clinically diagnosed
essential hypertension before age 60. GENOA has genome
wide measurement of exon-level gene expression profiles
in immortalized beta-lymphocyte cell lines and genome-
wide genotypes on about 800 individuals, which provides
a unique epidemiological opportunity to evaluate both the
cis and the trans effect of the variation in the Chr9p21 re-
gion on gene expression. Immortalized beta-lymphocytecell lines are not the most proximal tissue for examining
the atherosclerotic process, however, they provide an effi-
cient and robust way to examine the effects of DNA se-
quence variation on variation in gene expression since the
environmental conditions of the cells are the same across
individuals (i.e. environmental variation is minimized).
We also used a SNP-set based association method [31] to
examine the effects of all variants in the 9p21 region at
once for transcriptome wide gene expression analysis.Methods
Sample
The GENOA study is a community-based study of sib-
ships that aims to identify genes influencing blood pres-
sure [30,32]. Sibships with at least two adults with
clinically diagnosed essential hypertension before age 60
were recruited. All other members of the sibship were in-
vited to participate regardless of their hypertension status.
All subjects came from the Rochester, MN field center and
were non-Hispanic whites of European descent. Among the
participants, 801 individuals had both genome-wide SNP
data and gene expression data. The GENOA study was ap-
proved by the University of Michigan Health Sciences and
Behavioral Sciences Institutional Review Board and the
Mayo Clinic Institutional Review Board. Each participant
gave written informed consent.Genotyping and quality control of GWAS SNPs
GENOA participants were first genotyped using the Affy-
metrix Genome-wide Human SNP Array 6.0 platform.
The samples whose genotyping was not successful on the
Affymetrix 6.0 platform were re-genotyped using the Illu-
mina Human1M-DUO BeadChip (Illumina, 2010). For
each platform, participants were excluded if they had an
overall SNP call rate <95% or sex mismatch between
genotypic and phenotypic measurement. SNPs were ex-
cluded if they had an unknown chromosomal location or
a call rate less than 95%. These quality control filters re-
sulted in 668,293 SNPs in 1,386 subjects available from
the Affymetrix platform and 893,545 SNPs in 123 subjects
from the Illumina platform for analysis.
Principal component analysis was conducted as an add-
itional quality control step to identify and remove samples
with outlying genotype profiles. After forty-five outliers
were identified and excluded, a total of 1,464 individuals
had genotype data available for analysis.
For this analysis, imputation was done using the Euro-
pean reference panel (87 CEU, 98 TSI, 89 GBR, 93 FIN, 66
MXL, 55 PUR) from the 1000 Genome Project. Prior to im-
putation, SNPs were additionally filtered for minor allele
frequency (MAF) ≥ 0.01 and Hardy-Weinberg P-value ≥
0.001. MACH (v1.0.16) and Minimac (v 4.4.3) were used to
impute genotypes of unmeasured markers, up to total of
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and Minimac was used in the imputation stage.
After the above steps, 180 SNPs within the region of
Chr9p21 (chr9: 22,012,420-22,125,915 bp) that had imput-
ation quality score R2 greater than 0.9 and MAF greater
than 0.0025 were selected for analysis.
Gene expression profiling and quality control
RNA samples from cell lines established from peripheral
blood samples by Epstein-Barr virus transformation were
extracted using standard protocols. RNA quality was
assessed using the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies Inc., Foster City, CA) and quantified by spectro-
photometry using the Nanodrop ND-1000 (Nanodrop Inc.,
Wilmington, DE). All RNA samples used in the present
study yielded both anA260/A280 absorbance ratio greater
than 2.0 and a RNA Integrity Number (RIN) ≥ 8.
One μg of RNA was labeled using the WT Expression
labeling assay (Applied Biosystems/ Ambion, Foster City,
CA) including the labeling controls from the GeneChip
Eukaryotic Poly-A RNA Control Kit (Affymetrix, Santa
Clara, CA). Each step of the labeling protocol was moni-
tored using the Agilent 2100 Bioanalyzer or the Nanodrop
spectrophotometer, as recommended by the manufac-
turer. Hybridization buffer, Eukaryotic Hybridization Con-
trols, and OligoB2 controls were added to the cDNA
fragments just prior to hybridization to the Affymetrix
Human Exon 1.0 ST Array. Hybridization was performed
at 45°C for 17 hours. Following hybridization, the chips
were washed and stained with a phycoerythrin-strepavidin
conjugate and were scanned at the excitation wavelength
of 488 nm.
Array quality control was performed using Affymetrix
Expression Console™ (v 1.1) at the transcript level using
core-level probe sets. All array images passed visual in-
spection. Hybridization controls were all present with sig-
nal increases following concentration. Labeling control
signal strengths followed the order Lys < Phe < Thr < Dap.
Signal intensity plots were examined for raw and proc-
essed data to identify outliers. Summarization QC metrics,
including relative log expression (RLE), positive vs. nega-
tive ROC AUC and MAD-residual mean, were all within
the parameters suggested by Affymetrix.
Raw intensity data were processed using Multiple
Exon Array Preprocessing (MEAP) software. The PM-
BayesBG method was used for background correction.
This was followed by quantile normalization, expression
summarization and log2 transformation [33]. The expres-
sion summarization is multi-dimensional depending on
the user defined data type, which includes probeset, exon,
spliced variant or gene. The transcript (spliced variant)
level summary was used in this study. Annotation version
64 was used for our expression summarization. Exon ex-
pression intensities were summarized directly from probe-level expression values and MEAP annotation. Expression
summarizations for transcripts were calculated from exon
expression by linear algebra based on transcript records in
external databases. If the probes targeting an exon did not
have strong signals and thus caused low or no expression
of the exon, it may have resulted in a negative algebraic
solution. The transcript’s expression values were denoted
as missing in that case. If a transcript had a missing rate
greater than 10%, it was excluded from the analysis.
Principal component analysis on the exon level expres-
sion data was used to identify possible outliers, and none
were identified. We also verified sex assignment of the
samples by examining expression levels of genes on the Y
chromosome. Two individuals were excluded due to sex
mismatch. There were a total of 875 individuals who had
gene expression data. Among them, 801 individuals had
both gene expression and SNP data.
Statistical methods
To evaluate the cis effect, the association between each
SNP in the Chr9p21 region and the candidate transcripts
from the four adjacent genes were tested using linear
mixed models with each transcript as the outcome, SNP
as the predictor, and age, sex and batch as the covariates.
Familial correlation was adjusted by the random effect.
SNPs were coded additively. Since there were 8 tran-
scripts and 180 SNPs in total, the Bonferroni corrected
p value for each transcript was 3.47e-5. Among those
SNPs, we also specifically examined six known CAD risk
variants: rs7865618, rs10811650, rs1333040, rs10757274,
rs2383206, and rs1333045 [34].
In order to increase our power to detect trans effects,
SNP-set (Sequence) Kernel Association Test (SKAT) [31]
was used to test the association between gene expression
and the SNP-set within the Chr9p21 region. SKAT allows
different weights to be assigned to different variants ac-
cording to a hypothesis or existing knowledge. The default
weight follows a Beta(1,25) function, which assumes rare
causal variants have larger effects, and thus assigns larger
weights to rare variants. Beta(1,1) assumes all of the causal
variants have similar effect sizes and assigns equal weights
to all the variants. Beta(0.5,0.5) produces the Madsen &
Browning weights that have been a popular choice, which
also assigns weight based on the minor allele frequency
(MAF) but does not up-weight rare variants as much as
the Beta(1,25) function [35]. In order to assess the effect of
both rare variants and common variants, we applied all
three weighting schemes to the analysis. To adjust for fa-
milial correlation, we implemented a two-step approach.
First, the transcript level gene expression was adjusted for
familial correlation by a linear mixed model and the ran-
dom residual was saved. Second, SKAT was used to test
the association between the residual from the previous step
and all the SNPs within the Chr9p21 region, with batch,
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A total of 35,477 transcripts across the whole genome were
analyzed, false discovery rate (FDR) at 10% was applied to
adjust for multiple testing. To identify trans expression
quantitative trait loci (eQTLs) at the SNP level, we
followed up each SKAT association that had FDR q < 0.1
with single SNP analysis using all of the SNPs in the
Chr9p21 region. The statistical model was the same as the
model used for the cis effect analysis.
Since the transcripts across the genome are highly cor-
related, it is often too conservative to simply apply a strin-
gent criterion for association. Thus we also performed
gene set enrichment testing for transcripts at least nomin-
ally associated with the Chr9p21 region (p-value < 0.01) in
the Beta(1,25), Beta(1,1) and Beta(0.5,0.5) SKAT analyses.
DAVID [36] was used for gene set enrichment testing, in
which the background was set as the total of 35,477 tran-
scripts. The p-value of each gene set was calculated using
a modified Fisher exact test.
All statistical analyses were performed with R statis-
tical environment version 2.9.0 from R Project (http://
www.r-project.org/). The authors had full access to the
data and take responsibility for its integrity. All authors
have read and agree to the manuscript as written.
Results
There were 801 individuals who had both expression pro-
files and SNP data. There were 337 men and 464 women,
and the mean age was 59.2 years. The majority of the par-
ticipants (75.9%), by study design, had hypertension.
There were 82 subjects with a history of coronary artery
disease.
The Chr9p21 haplotype block is a 113.5-kb region from
base pair 22,012,420 to 22,125,915 on chromosome 9 [18].
The adjacent four genes of this region are ANRIL,
CDKN2A, CDKN2B and C9orf53 and the available tran-
scripts are presented in the first column in Table 1. In ourTable 1 Top SNPs associated with each transcript
Transcript ID Top SNP Coded allele Non coded allele
ANRIL
ENST00000428597 rs7865618 A G
ENST00000422420 rs1759417 C T
C9orf53
ENST00000441769 rs662463 G A
CDKN2A
ENST00000380151 rs647188 T G
ENST00000361570 rs647188 T G
ENST00000304494 rs647188 T G
CDKN2B
ENST00000380142 rs2095144 G A
ENST00000276925 rs1333040 T Cdata, ANRIL has 2 transcripts, CDKN2A has 3 transcripts,
CDKN2B has 2 transcripts and C9orf53 has 1 transcript.
The effect of each of the 180 Chr9p21 SNPs on each tran-
script was evaluated. The SNP with the strongest associ-
ation with each transcript is shown in Table 1. The
Bonferroni corrected alpha level is 3.47e-5. Among the 8
SNPs shown in Table 1, only the top SNP for the ANRIL
transcript ENST00000428597 was significantly associated
after Bonferroni correction. No other transcripts were sig-
nificantly associated with any SNPs in the Chr9p21
region.
Next, we plotted the p value of the association between
the ANRIL transcript and each SNP against the chromo-
some position in Figure 1A. There were a total of 18 SNPs
that were significantly associated with the mRNA expres-
sion of the ANRIL transcript ENST00000428597 at the
Bonferroni corrected p value. As shown in Figure 1A,
almost all the SNPs that were associated with the ANRIL
transcript are in linkage disequilibrium with the top
SNP rs7865618. The mRNA expression level of ANRIL
transcript ENST00000428597 was plotted against SNP
rs7865618 as shown in Figure 1B. One increased copy
of A in rs7865618 is associated with a 7% increase in
the ANRIL transcript ENST00000428597 on the log2 scale,
which corresponds to a 5% increase on the original scale.
We also specifically examined the association between
known CAD risk SNPs in the Chr9p21 region and the
ANRIL transcript ENST00000428597, and the results are
summarized in Table 2. Our top SNP, rs7865618, is in-
cluded in the group of CAD risk SNPs. Moreover, all of
the six candidate SNPs showed a trend of association with
this transcript, and three were significantly associated at a
nominal level (p = 0.05). Because we know that there is
strong linkage disequilibrium in the Chr9p21 region, we
examined the correlation among the six candidate SNPs
in our dataset and they were all correlated with each other
(absolute r ranges from 0.538 to 0.976). For all of theCoded allele frequency Parameter estimate SE P-value
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Figure 1 The association between the ANRIL transcript ENST00000428597 and the SNPs in the Chr9p21 region. A. The relationship between the
ANRIL transcript ENST00000428597 and the SNPs in the Chr9p21 region. SNPs are plotted by chromosomal position against the –log(p-value) of
their association with the ANRIL transcript ENST00000428597. The most significant SNP is shown as a purple circle, and indicated by an arrow. The
SNPs surrounding the most significant SNP are color-coded to reflect their linkage disequilibrium with this SNP as shown in the inset (taken from
pairwise r2 values from the 1000 Genomes Project EUR database). Genes and the position of exons, as well as the direction of transcription, are
noted below the plots (data from UCSC Genome Browser). B. Plot of the mRNA expression of ANRIL transcript ENST00000428597 and the top SNP
rs7865618. The mRNA expression level (log2 scale) is plotted against each genotype and is shown in red. The black boxplot is added on top of
the scatterplot to show the median and interquartile range of expression level for each genotype.
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always increases the mRNA expression of the transcript.
In order to better understand the potential importance
of genetic variation in this chromosomal region on the
larger metabolic processes underlying the atherosclerotic
processes, we used the SKAT method to perform atranscriptome-wide assessment of the Chr9p21 region’s
trans effect. The top transcripts that were associated
with the Chr9p21 region through trans effects are listed
in Table 3. When the Beta(1,25) weight was used, four
transcripts from four genes showed significant asso-
ciation with the Chr9p21 region. They were DUT
Table 2 The association between ANRIL ENST00000428597 and known CAD risk variants
CAD risk SNP Risk allele Coded allele Non coded allele Coded allele frequency Parameter estimate SE P-value
rs7865618 A A G 0.569 0.070 0.0155 8.58e-06
rs10811650 G G A 0.490 0.043 0.0154 0.0058
rs1333040 T T C 0.605 0.028 0.0158 0.0755
rs10757274 G G A 0.490 0.030 0.0152 0.0522
rs2383206 G G A 0.504 0.033 0.0153 0.0345
rs1333045 C C T 0.543 0.030 0.0158 0.0588
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CASP14 (ENST00000427043), and ABCA1 (ENST000
000374736). When the Beta(1,1) and Beta(0.5, 0.5) weight-
ing schemes were used, the top transcript from those
two tests was the same for the same gene: DHRS9
(ENST00000412271). However, this transcript was not
significant after controlling for multiple testing. As a com-
parison, we also provide the SKAT test results for the
ANRIL transcript (ENST00000428597) that has shown
significant association with multiple SNPs in the Chr9p21
region. This transcript was significant in the SKAT test
when the weights Beta(1,1) or Beta(0.5,0.5) were applied,
but was not significant when the weight Beta(1,25) was
applied. As shown in Table 3, the transcript DHRS9
(ENST00000412271) was more significant than the ANRIL
transcript, which is known to be associated with the
Chr9p21 region. Thus, this gene was also included for the
following single SNP analysis.
Next, we looked at the associations between transcripts
and single SNPs using the identified top trans-effected
transcripts and all of the SNPs in the Chr9p21 region. The
top SNP for each transcript is listed in Table 4. As shown
in Table 4, the top SNPs (rs16923583, rs41386451,
rs16905597) for DUT, EIF1AY, CASP14 and ABCA1 wereTable 3 The top transcripts associated with the Chr9p21 regi
Transcript N SKAT SKAT
Beta(1,25) Beta(1,1)
P value P value
Top transcripts when SKAT_Beta(1, 25) was used
ENST00000331200 800 8.19e-07 0.905
ENST00000361365 781 1.55e-06 0.762
ENST00000427043 796 5.79e-06 0.909
ENST00000374736 801 1.01e-05 0.719
Top transcript when SKAT_Beta(1, 1) was used
ENST00000412271 749 0.608659 3.05e-05
Top transcript when SKAT_Beta(0.5, 0.5) was used
ENST00000412271 749 0.608659 3.05e-05
cis transcript
ENST00000428597 801 0.47 0.002013all rare variants (MAF approximately 0.005). Moreover,
we found that the top 4 SNPs for all four of these genes
were the same rare variants (rs16923583, rs41386451,
rs16905597 and rs73650008), although the rank of the
associations are different across genes (Additional file 1:
Table S1). The top SNP (rs4977756) for the transcript
DHRS9 was a common SNP (MAF = 0.44), which was also
correlated with all of the CAD risk SNPs in the Chr9p21
region (absolute r ranges from 0.58 to 0.83). These results
are consistent with the underlying assumptions of the
three different SAKT weighting schemes that have been
used in this study. One common problem for rare variant
analysis is that the detected associations are often driven
by one or a few samples. That is what we observed in our
study as well (Additional file 2: Figure S1). Thus, func-
tional studies are needed to validate our findings.
To further examine the trans effect in multiple tissues
and across cohorts, we searched the above identified asso-
ciations between gene expression levels and Chr9p21 SNPs
(SNP rs4977756 with DHRS9 as well as the 4 rare variants
with ABCA1, CASP14, DUT, EIF1AY) in two public eQTL
databases, GENe Expression VARiation (Genevar) [37] and
the Genotype-Tissue Expression project (GTEx) [38]. We
preferentially focused on the HapMap3 project in Genevaron from the SKAT test
SKAT FDR
q value
Gene Location
Beta(0.5,0.5)
P value
0.416 0.0276 DUT 15q21
0.360 0.0276 EIF1AY Yq11
0.490 0.0685 CASP14 19p13
0.387 0.0893 ABCA1 9q31
3.38e-05 0.9998 DHRS9 2q31
3.38e-05 0.9998 DHRS9 2q31
0.001907 1 ANRIL 9p21
Table 4 The top SNPs associated with the trans-effected transcripts identified by SKAT
Gene Transcript Top SNP Coded allele Non coded allele MAF Beta SE P value
DUT ENST00000331200 rs16923583 T A 0.9944 1.07 0.187 2.14e-08
EIF1AY ENST00000361365 rs41386451 A C 0.9952 1.77 0.377 3.66e-06
CASP14 ENST00000427043 rs16923583 T A 0.9944 1.25 0.236 1.95e-07
ABCA1 ENST00000374736 rs16905597 G A 0.9951 -0.58 0.108 1.65e-07
DHRS9 ENST00000412271 rs4977756 A G 0.5635 0.35 0.089 9.84e-05
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DHRS was found to be associated with rs4977756 in
transformed B-lymphoblastoid cells (TBLs) in European
Americans (CEU, p = 0.017) and the direction of effect
was consistent with the observed effect direction in
GENOA. However, there was not a significant association
between rs4977756 and any heart related tissue in GTEx.
Only two of the four rare variants, rs16923583 and
rs16905597, were available in a small number of non-CEU
populations in Genevar, and the associations were not sig-
nificant. The other two rare variants were not available in
either of the databases.
As an alternative, we looked up the association between
the six known common Chr9p21 CAD risk SNPs (Table 2)
and the genes DUT, EIF1AY, CASP14 and ABCA1. In the
Genevar database, we found that rs10811650 was associ-
ated with ABCA1 expression (p = 0.015) in TBLs in CEU
and CASP14 expression (p = 0.0017) in an African popula-
tion (LWK). Also, rs1333040 was associated with DUT
expression (p = 6.0 × 10-4) in a separate African population
(YRI). Moreover, in the GTEx database, ABCA1 was asso-
ciated with four SNPs (rs1333045: p = 0.009; rs2383206:
p = 0.002; rs10757274: p = 0.003; rs7865618: p = 0.008) in
74 artery aorta samples. EIF1AY was associated with the
same set of SNPs in 87 heart left ventricle samples
(rs1333045: p = 0.006; rs2383206: p = 0.02; rs10757274:
p = 0.005; rs7865618: p = 0.007). This association between
Chr9p21 SNPs and gene expression in left ventricular and
aorta tissue provide suggestive evidence that the Chr9p21
region has trans effects in relevant tissues for several of
the genes that we have identified.
To discover the potential biological importance of
trans-effected genes, we used the KEGG Pathway for
gene enrichment analysis. For the top transcripts in
Beta(1,25), there was no significantly enriched gene set
with p-value < 0.1. However, for the top transcripts in
Beta(1,1) and Beta(0.5,0.5), there were two and three
gene sets, respectively, that were enriched at a nominal
p-value < 0.1. As shown in Table 5, the enriched path-
ways include retinol metabolism and TGF-β signaling
for Beta(1,1), and all of the same pathways plus N-Glycan
biosynthesis for Beta(0.5,0.5). The top enriched pathway is
retinol metabolism, in which DHRS9 (ENST00000432060,
ENST00000412271), ADH1 (ENST00000394887), DHRS4L2(ENST00000335125), LRAT (ENST00000336356) and
CYP26B1 (ENST00000001146) are significantly associated
with the Chr9p21 region. One of the two transcripts of
DHRS9 (ENST00000412271) is the most significant trans-
effect gene in Beta(1,1) and Beta(0.5,0.5).
Discussion
Even though the Chromosome 9p21 region has been impli-
cated as a hotspot associated with CAD, it continues to be
a challenge to understand the immediate biological and
functional effects of variants in that region. Studying the as-
sociation between genetic variants and gene expression
variation is valuable for connecting variation at the DNA
sequence level to that at the RNA level. In this study, we
used a large family-based cohort where both genotype and
gene expression were measured on the same individuals to
evaluate both the cis and the trans effects of the genetic
variants in the Chr9p21 region on the RNA expression at
the transcript level. It was found that most CAD associated
SNPs in the Chr9p21 region were highly associated with
the expression of the ANRIL transcript ENST00000428597.
In addition, we found that the Chr9p21 region was also as-
sociated with gene expression of a few distant functional
genes and pathways. These results suggest that the genetic
effect of risk variants in Chr9p21 region on susceptibility to
CAD is likely to be mediated through both cis and trans
effects.
There have been numerous studies looking at the local
functional impact of the Chr9p21 variants on gene expres-
sion in a variety of tissues and cells [21-27]. All of these
studies consistently showed the CAD risk variants in the
Chr9p21 region were associated with ANRIL expression
and have very little effect on the other local transcripts. For
example, earlier studies found that a CAD risk variant was
associated with reduced expression levels of ANRIL in
purified peripheral blood T-cells, whole blood cells and
vascular smooth muscle cells [22,24,27]. However, these
studies only examined ANRIL expression at the whole gene
level and did not take alternative splicing into account,
which could have masked the true effect. Our study exam-
ined the mRNA expression at the transcript level and
found that SNP rs7865618, which is a CAD risk variant
[6,34], was associated with the gene expression of the
ANRIL long transcript ENST00000428597. The risk variant
Table 5 Gene set enrichment testing of KEGG pathway for nominally significant transcripts in Beta(0.5,0.5) and
Beta(1,1) (p-value < 0.1)
Term Number of genes P value Enriched transcript
Beta(0.5,0.5) hsa00830:Retinol metabolism 5 0.016 ENST00000394887, ENST00000001146, ENST00000432060,
ENST00000412271, ENST00000336356
hsa04350:TGF-beta signaling pathway 4 0.056 ENST00000416274, ENST00000224764, ENST00000394092,
ENST00000401753
hsa00510:N-Glycan biosynthesis 3 0.077 ENST00000393487, ENST00000413355, ENST00000250498
Beta(1,1) hsa00830:Retinol metabolism 6 0.002 ENST00000335125, ENST00000394887, ENST00000001146,
ENST00000432060, ENST00000412271, ENST00000336356
hsa04350:TGF-beta signaling pathway 4 0.056 ENST00000416274, ENST00000224764, ENST00000394092,
ENST00000401753
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study. In addition to SNP rs7865618, we also examined five
other CAD-associated SNPs and found that two of them
were associated with ANRIL expression at a nominal level
(p value < 0.05) and the other three also showed a non-
significant trend for association. The directions of the ef-
fects were the same for all of the CAD risk variants we ex-
amined in our study. This replicated the previous report
that the same transcript was increased in the carriers of
the risk haplotype in peripheral blood mononuclear cells
and whole blood cells [25]. However, Jarinova et al. also
specifically investigated the relationship between CAD risk
variants and different splicing variants of ANRIL and re-
ported that the CAD risk variant was associated with a
decreased amount of the same long variant in whole blood
cells [21]. Congrains et al. did not observe a strong associ-
ation between the risk variants and the ANRIL long tran-
script in vascular smooth muscle cells [26].
One possible reason that the directions of effects are
inconsistent is that these studies were performed in differ-
ent tissues and have used different assays to target different
exons. The transcript ENST00000428597 was the longest
transcript of the gene ANRIL, which includes all 19 exons.
Our study used the Affymetrix Human Exon 1.0 ST Array,
which was designed to measure every exon in the gene and
then summarize them into transcript level measurements
based on known transcript composition. The other three
studies used quantitative reverse transcription polymerase
chain reaction assays with different probes in their studies
(Holdt et al. targeted exon 18-19, Jarinova et al. targeted
exon 15-16, Congrains targeted exon 17-18) [21,25,26]. As
shown by Folkersen et al., ANRIL has many novel tran-
script variants depending by the tissue type [23]. Thus it is
possible that different transcripts were measured in differ-
ent studies or the same transcript behaved differently in
different tissues and environments. A recent functional
study suggests that the CAD risk variants promote ANRIL
expression by disrupting STAT1 binding [39]. Nonetheless,
taken together these results along with the fact that ANRILis expressed in cells and tissues that are affected by athero-
sclerosis [27,40] and are correlated with atherosclerosis se-
verity [25,26], they suggest that ANRIL plays an important
role in mediating the genetic effect of the Chr9p21 region
on the susceptibility of atherosclerosis.
There are several ways that the noncoding RNA ANRIL
can alter expression of associated protein coding genes,
which include RNA interference, gene silencing, chroma-
tin remodeling, and DNA methylation [41]. Recent studies
on animals found that ANRIL knockdowns showed a sub-
stantial reduction of cellular proliferation, which is known
to play an important role in atherosclerosis [42,43]. The
important role of ANRIL on cell growth has also been ob-
served in human vascular smooth muscle cells [26,27].
Other evidence suggests that ANRIL may also affect vari-
ous genes by trans effect [44-46]. Further studies are
needed to clarify the mechanism involved.
The present study is the first one that has focused on
the trans effect of the variants in the Chr9p21 region
across the whole genome. SKAT is a powerful SNP set
association test, which requires very few assumptions [31].
We used this test to screen the whole genome and found
that five transcripts from five genes were at least nomin-
ally associated with the Chr9p21 region. We also exam-
ined the association between the transcripts identified via
trans analysis and single SNPs within the Chr9p21 region,
and we found several trans-eQTL SNPs, including both
rare and common variants. The common trans-eQTL
SNP rs4977756 was in the same linkage disequilibrium
block with known CAD risk variants, and its association
with DHRS9 was supported by the same signal observed
from the same tissue in the HapMap CEU sample. Al-
though the other rare trans-eQTL SNPs were not available
in the public database, we did examine the relationship be-
tween gene expression in our identified trans-effected
genes and common CAD risk SNPs in the Chr9p21 re-
gion, and we found quite a few trans-eQTL SNPs. This
provides evidence that the Chr9p21 region is indeed asso-
ciated with the top trans-effected genes identified by
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sample size are needed to validate our findings.
Among the trans-effected genes identified by SKAT, the
most well-known gene is ABCA1, which is also located on
chromosome 9. It encodes a membrane-associated protein
that is a member of the superfamily of ATP-binding cas-
sette (ABC) transporters. The ABC protein transports
various molecules across membranes and has been shown
to be an important regulator for cholesterol efflux from
peripheral cells, and mutations in ABCA1 contribute to
low HDL [47-49]. It is known that low HDL cholesterol is
an independent risk factor for CAD [50]. Given its role in
lowering HDL cholesterol, loss of function mutations in
ABCA1 would increase CAD risk. This supposition has
been supported by the observation that the mutations in
ABCA1 are associated with coronary artery calcification, a
subclinical trait of atherosclerosis [51] as well as CAD
[52]. The function of ABCA1 in the development of ath-
erosclerosis has also been confirmed in animals. ABCA1
knockout mice develop larger atherosclerotic lesions, and
overexpression of ABCA1 inhibits the progression of ath-
erosclerotic lesions [53-55]. It was suggested that ABCA1
protects against atherosclerosis by removing cholesterol
from macrophages in the artery wall and therefore pre-
vents the formation of foam cells, which are critical for
the formation of atherosclerotic plaque [56,57]. Though
the Chr9p21 region has been implicated in the etiology of
atherosclerosis for a long time, this is the first time that
we have observed an association between this chromo-
somal region and a functional gene for atherosclerosis.
Understanding the cellular mechanism underlying this as-
sociation is a very important next step to advancing our
understanding of the relationship between Chr9p21 and
atherosclerosis.
The four other genes identified as significantly associ-
ated with the Chr9p21 region are CASP14, EIF1AY, DUT
and DHRS9. CASP14 plays a central role in the execution
phase of cell apoptosis and is overexpressed in tumors
[58]. EIF1AY is on the Y chromosome and is overex-
pressed in men who have experienced a stroke [59]. DUT
encodes an essential enzyme of nucleotide metabolism,
which is vital to DNA replication [60]. DHRS9 encodes an
enzyme that is involved in the metabolism of retinol [61].
Very little is known about these genes in terms of their
roles in CAD, so future studies will be necessary.
Since the transcripts across the genome are highly cor-
related, applying a stringent p-value cutoff to trans-effect
analyses may be too conservative. Gene enrichment test-
ing is a powerful way to reveal potential influential tran-
scripts and pathways. According to the gene set analysis,
the trans-regulated genes predicted by Beta(1,1) and
Beta(0.5,0.5) are enriched in several pathways. Retinol me-
tabolism, the top pathway, has shown to have important
effects on atherogenesis, endothelial function, vascularcalcification and lipid metabolism [62]. It is also correlated
with alcoholic liver disease in which alcoholic patients dis-
play hepatic total retinol levels that are progressively lower
with increasing severity of liver disease [63]. Notably,
DHRS9 has two transcripts within the nominally signifi-
cant transcripts identified by the SKAT test, increasing the
credibility that this gene shows a true trans-effect. ADH1,
one class of alcohol dehydrogenase, catalyzes the oxida-
tion of alcohols to aldehydes and also metabolizes retinol,
hydroxysteroids, and lipid peroxidation products. It affects
cardiovascular function by regulating alcohol digestion as
well as via a direct effect on the vasculature [64].
Increased expression of CYP26B1 may aggravate athero-
sclerosis [65].
N-glycan biosynthesis is another pathway that was
enriched in the gene set analysis. N-glycans located at the
surface of the endothelium are responsible for interactions
with monocytes. A previous study has demonstrated that
N-glycans are increased on the endothelial cell surface at
sites of early human lesion development and are effectors
of monocyte adhesion during atherogenesis [66]. The
MAN1A2 gene, which was in this gene set, was re-
ported to be down-regulated by TNFα and is part of
an inflammatory mechanism in the pathological process
of atherosclerosis.
Activation of the TGF-β pathway is well recognized as
the most important feature in the pathogenesis of cardiac
remodeling and fibrosis. It also plays a crucial role in the
regulation of vascular function. A series of papers reveals
the effects of TGF-β signals in angiogenesis and athero-
sclerosis [67]. BMPR1A and SMAD1 in our gene set are
two core components in BMP pathway, which has shown
to be related to pulmonary arterial hypertension and vas-
cular calcification. These results all suggest that the risk
variants of CAD in the Chr9p21 region may exert the
trans effect by modulating the expression of genes respon-
sible for critical functions involved in CAD.
There are a few limitations of the current study. First, as
there is a considerable amount of gene-expression vari-
ation among populations [68], these results may not be ap-
plicable to other populations. For example, although the
GENOA sample was a community-based sample of sib-
ships selected on hypertension criteria, the frequency of
effects could be different from other populations or a rep-
resentative population-based sample of unrelated individ-
uals. However, our previous contributions to studies in
this region do not indicate significant allele frequency dif-
ferences from other population-based epidemiological
samples of unrelated non-Hispanic whites [69]. Second,
transformed beta-lymphocytes were used in this study,
and thus our results cannot be directly applied to other
tissues in the in vivo environment. Third, our sample size
is relatively small for a transcriptome-wide association
analysis.
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gene expression profiles in epidemiologic samples, investi-
gating both cis and trans effects to characterize potentially
functional elements in genomic regions identified by
GWAS is an important area of research. Considering the
limitations of our particular study, future epidemiologic
studies with larger sample sizes and more ethnically-
diverse populations are needed to replicate our findings.
In addition, gene expression analyses with rare variants
that are conducted in heart related tissue are another im-
portant next step for replication. However, whole genome
scale transcriptome association analysis only serves as a
screening procedure to provide potential targets for the
research community. Thus, functional studies are also
needed to examine how genetic variation in the Chr9p21
region plays a role in the etiology of CAD.
Conclusions
In conclusion, we used a novel SNP-set based method to
specifically examine the genetic effect of the CAD risk vari-
ants of the Chr9p21 region on the transcript level gene ex-
pression across the whole genome. We replicated the
previous finding that the ANRIL long variant is highly asso-
ciated with the CAD risk variants. Moreover, we provide
the first evidence that variation in the Chr9p21 region is as-
sociated with important functional genes and pathways,
which play an important role in the progression of athero-
sclerosis. Taken together, this suggests that DNA sequence
variation in the Chr9p21 region may affect CAD through
both cis and transmechanisms.
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